ARCHIVES

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

Senate To NCI: Return To Old Guidelines, Stop “Mixed Messages” On Mammography

February 14, 1997

Survival Rates Same For Two Treatments For Eye Cancer: Radiation Or Removal

July 27, 2001

HPV Vaccines Should Be Priority, Say President’s Cancer Panel

March 7, 2014

In Brief: LYNNE PENBERTHY Was Named Associate Director For Surveillance Research In NCI’s Division of Cancer Control and Population Sciences

November 8, 2013

More Patients Get Screened, Colorectal Death Rates Drop

July 29, 2011

NCI Still Trying To Broaden Group B Drug Distribution

May 5, 1978